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Abstract: Depot specific expansion of orbital-adipose-tissue (OAT) in Graves’ Orbitopathy (GO) is
associated with lipid metabolism signaling defects. We hypothesize that the unique adipocyte biology
of OAT facilitates its expansion in GO. A comprehensive comparison of OAT and white-adipose-tissue
(WAT) was performed by light/electron-microscopy, lipidomic and transcriptional analysis using
ex vivo WAT, healthy OAT (OAT-H) and OAT from GO (OAT-GO). OAT-H/OAT-GO have a single
lipid-vacuole and low mitochondrial number. Lower lipolytic activity and smaller adipocytes of
OAT-H/OAT-GO, accompanied by similar essential linoleic fatty acid (FA) and (low) FA synthesis to
WAT, revealed a hyperplastic OAT expansion through external FA-uptake via abundant SLC27A6
(FA-transporter) expression. Mitochondrial dysfunction of OAT in GO was apparent, as evidenced
by the increased mRNA expression of uncoupling protein 1 (UCP1) and mitofusin-2 (MFN2) in
OAT-GO compared to OAT-H. Transcriptional profiles of OAT-H revealed high expression of Iroquois
homeobox-family (IRX-3&5), and low expression in HOX-family/TBX5 (essential for WAT/BAT
(brown-adipose-tissue)/BRITE (BRown-in-whITE) development). We demonstrated unique features
of OAT not presented in either WAT or BAT/BRITE. This study reveals that the pathologically enhanced
FA-uptake driven hyperplastic expansion of OAT in GO is associated with a depot specific mechanism
(the SLC27A6 FA-transporter) and mitochondrial dysfunction. We uncovered that OAT functions
as a distinctive fat depot, providing novel insights into adipocyte biology and the pathological
development of OAT expansion in GO.
Keywords: Graves’ orbitopathy; orbital adipose tissue; WAT; BAT and BRITE; fatty acid uptake;
hyperplasic adipocyte expansion
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1. Introduction
Orbital adipose tissue (OAT) is dysregulated in the disfiguring and sight-threatening disease of
the orbit, Graves’ Orbitopathy (GO, also called thyroid eye disease) [1,2]. In the healthy state, OAT
acts to cushion and protect the orbital contents, extra-ocular muscles, blood vessels and nerves, in
the bony orbit [3]. In GO, the uncontrolled expansion of OAT results in periorbital swelling, pain,
redness, proptosis, double vision, and in some cases visual loss, which develops mainly in the context
of the associated autoimmune condition, Graves’ disease [1,2]. Previous studies have examined
the autoimmune/inflammatory changes in OAT in GO with a focus on activation pathways via two
main targeted receptors, the thyrotropin receptor (TSHR) and insulin like growth factor 1 receptor
(IGF1R) [4–8]. However, little attention has been directed to basic orbital fat biology and how it changes
in patients with GO.
Uncovering the biological differences between OAT and white adipose tissue (WAT) will enhance
our understanding of the pathophysiology of the disease. Known differences include: (i) OAT is a
neural crest derived fat depot within the orbit where WAT and brown adipose tissue (BAT) have a
mesodermal origin [9,10]; (ii) in contrast to the increasing WAT mass in obesity worldwide, there are
no reports of OAT expansion or proptosis in obesity [11]; and (iii) in patients with GO, a marked
increased volume of OAT is due to adipogenesis of preadipocytes/fibroblasts (PFs) [12], while WAT
in the same individual typically shrinks due to hyperthyroidism [13]. We previously reported depot
specific signaling networks involving the PI3K/Akt/mTORC1/FOXOs pathways present in PFs derived
from human OAT distinct from WAT [14,15], and these appear to play essential roles in OAT expansion
in GO [2].
Adipose tissue plays a fundamental role in regulating whole-body energy homeostasis including
adipogenesis, lipid uptake, de novo lipogenesis, unsaturated fatty acids (uFAs) conversion and lipolysis,
as well as producing regulatory hormones such as adiponectin (ADIPOQ) and leptin (LEP) [16]. WAT
as a ‘flexible energy reservoir’ that supplies free fatty acids (FAs) when needed, while BAT functions
to burn FAs to generate cold-induced adaptive thermogenesis [17]. There is a single lipid vacuole in
the adipocytes of WAT contrasting to the multi-loculated appearance of BAT [18]. BRITE (BRown in
whITE) adipocytes are found in human WAT and BAT depots [19,20]. BAT/BRITE is distinguished
from WAT by high expression levels of uncoupling protein 1 (UCP1), which dissipates energy as heat
from the abundant mitochondria present in adipocytes [17,20]. Adipogenesis is a lineage specific
differentiation process that occurs in PFs to form adipocytes. In this process, lipid accumulates
intracellularly as triglyceride from the uptake of external FAs and/or de novo lipogenesis from internal
carbohydrates. To expand adipose tissue, BAT increases adipocyte number (hyperplasia) [21], while
WAT is mainly considered to expand by increasing the size of adipocytes (hypertrophy), although
variation in hyperplasia capacity has been observed between different WAT depots [22].
OAT shares several features with BAT. For instance, adiponectin overexpression in a murine model
showed a selective expansion of fat depots including intrascapular (known to be BAT) and OAT [23].
Furthermore, increased UCP1 expression in OAT has been observed from a recent TSHR-induced
GO mouse model [24]. We have demonstrated that TSHR activation plays an important role in the
up-regulation of UCP1 in both OAT and WAT [19,25], also suggesting that OAT is closely related to
BAT. We hypothesize that the unique adipocyte biology of OAT provides the link to its expansion in
GO. In this study, we characterize the OAT fat depot, by morphology, lipidomic and transcriptional
analysis, to gain further insights into OAT adipocyte biology and possible disease mechanisms of GO.
2. Results
2.1. Adipocytes Size and Mitochondria Count per Adipocyte
We examined ~100 to 500 adipocytes per ex vivo human adipose sample and observed no gross
difference in morphological appearance from WAT and healthy OAT (OAT-H), or OAT from GO patients
(OAT-GO) by light microscopy (Figure 1A). In particular, adipocytes from WAT and OAT-H/OAT-GO
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had a single lipid vacuole, in contrast to the multi-loculated appearance of classical BAT [18]. However,
adipocytes from OAT-H/OAT-GO were substantially smaller (by about 50%) compared with WAT
(Figure 1B).
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Figure 1. Adipocyte and mitochondria analysis of white-adipose-tissue (WAT), healthy orbital adipose
tissue (OAT-H) and OAT- Graves’ Orbitopathy (GO). (A) Representative photomicrographs show
toluidine blue-stained sections of WAT, OAT from healthy individuals (OAT-H) and OAT from GO
patients (OAT-GO) (scale bar 50 µm) by light microscopy; and (B) area of adipocytes (µm2) was
investigated. (C) Representative photomicrographs of adipocyte mitochondria (Mt) are shown by
electronic microscopy (scale bar 200 nm); (D) numbers of mitochondria (Mt) per adipocyte, (E) length
and width (nm) of mitochondria from each study group were analyzed. Histograms = mean ± SEM of
all samples studied, p value indicated in the figure, ** as p < 0.01, **** as p < 0.0001.
Enumeration of mitochondria in each group by electron microscopy (Figure 1C) showed 0 to 25
profiles per adipocyte field of view with no significant difference in the number of mitochondria per
adipocyte between WAT and OAT-H (Figure 1D). Interestingly significantly fewer mitoch ndria per
adipocyte were observed in an active OAT-GO sample compared with WAT and OAT-H (Figure 1D).
No significant differences of length and width of mitochon ria were seen comparing OAT-H, OAT-GO
and/or W T (Figure 1E).
2.2. Differences in OAT versus WAT or BAT/BRITE in Marker Genes
Expression of marker genes for WAT and BAT/BRITE was analyzed by QPCR in ex vivo samples
from OAT-H, OAT-GO and WAT. Substanti lly down-regulated LEP (Leptin, WAT marker) and
little expression of UCP1 (BAT/BRITE marker) were observed in OAT-H when compared with WAT
(Figure 2A,B). Expression of UCP1 transcripts were increased in OAT-GO compared to OAT-H (4- to
291-fold, p = 0.02) reaching levels comparable or greater than WAT (Figure 2B). The mitochondria and
BAT/BRITE marker MFN2 showed a substantially lower expression in OAT-H compared with WAT
(Figure 2C), while significantly increased MFN2 transcripts were observed in OAT-GO compared to
OAT-H and reached levels similar to WAT.
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Figure 2. OAT is neither WAT nor brown adipose tissue (BAT)/BRown-in-whITE (BRITE). (A–C), QPCR
analysis of OAT-H (n = 4), OAT-GO (n = 9) and WAT (n = 6) ex vivo fat. LEP (WAT marker) and
UCP1 (BAT/BRITE marker) were analyzed using the relative ratio of gene expression by QPCR, and
housekeeper gene APRT served as the reference gene. MFN2 (mitochondrial/BAT/BRITE marker) was
analyzed by standard PCR, densitometry was measured and corrected to the house-keeping gene
(APRT), MFN2 expression relative to APRT is presented. Histograms = mean ± SEM of all samples
studied. * p < 0.05; *** p ≤ 0.005, **** p ≤ 0.0006.
2.3. FA Composition of Triglyceride Comparing OAT and WAT
Lipidomic analysis by Gas Chromatography (GC) using paired ex vivo OAT-H and WAT from
three healthy ndividuals, revealed a simila level of 18:2 (linoleic), an essential FA which is derived
from external sources only (~12% triglyceride comp sition) (Figure 3A). However, difference in oth r
aspects of FA composition were observed with less un aturated FAs (uFAs), 16:1 (palmitoleic), 14:1
(myristol ic), 18:ω3 (α-linolenic) and 20:4 (arachidonic), contrasting with higher saturated FA18:0
(stearic) in OAT-H (4.11 ± 0.53%) compared with paired WAT (2.75 ± 0.26%) samples (Figure 3B,C). No
differences in other saturated ( 2:0, 14:0 and 16:0) or unsaturated (18:1, 18:1v, 20:5, 22:5 and 22:6) FAs
were seen wh n comparing WAT with OAT-H (Figure 3).
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Figure 3. Depot specific fatty acid (FA) composition in OAT. Triglyceride composition of paired ex
vivo fat tissues of OAT-H and WAT from three female individuals, also 3 unpaired ex vivo OAT-GO
from female GO patients were analyzed by gas chromatography. Data presented as FAs percentage of
triglyceride. (A) FAs of 16:0, 18:1, 18:2; (B) FAs of 14:0, 16:1, 18:0, 18:1v, 18:ω3; (C) FAs of 12:0, 14:1, 20:4,
20:5, 22:5, 22:6. Histograms = mean ± SEM of all samples studied. * p < 0.05.
Int. J. Mol. Sci. 2020, 21, 9145 5 of 18
We also conducted triglyceride FA compositional analysis on non-paired OAT samples from
GO patients and observed similar FA composition in OAT-GO compared to OAT-H, including the
significantly increased 18:0 and decreased 18:ω3 FAs compared to WAT (Figure 3); however, the
differences in expression of 16:1, 14:1 and 20:4 in OAT-GO compared to WAT, were no longer significant.
2.4. Whole Transcriptome Analysis of Lipid Metabolisms in OAT Compared to WAT
1. To better understand OAT, transcriptional profiles were analyzed by RNA sequencing (RNAseq)
in ex vivo fat tissue samples of OAT-H (n = 4) compared to WAT (n = 5). A total of 60,668 genes
were in the genome build and 23,766 genes (total counts across all samples > 1) were analyzed
(Table S1A). Prior to differential gene expression (DGE) analysis, a good fit normalized count of
genes from all samples for DESeq2 model had been shown by shrinkage estimation of dispersion
plots (Figure 4A), in which the majority of genes were scattered around the curve of expected
dispersion value. At sample-level, Figure 4B showed similar distribution patterns across all
samples at lower, median and upper quantiles and counts for outlying features.
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Figure 4. Transcriptional profiles of OAT comparing WAT. Differential gene expression (DGE) analysis
was performed using a DESeq2 model generated from ex vivo female samples of OAT-H (n = 4) and
WAT (n = 5) (R/Bioconductor DESeq2 package). (A) Shrinkage estimation of dispersion plots provided
a visual means of examining dispersion estimates of genomic features relative to average expression
strength [26]. Black points represent per gene gene-wise maximum likelihood estimates (MLE). The
red curve represents the overall trend of the dispersion to mean dependence. Blue points represent
gene-wise estimates following shrinkage towards the mean (correction for noise). Black points circled
in blue are dispersion outliers that are not shrunk towards the DESeq2 fitted model. (B) Sample level
box plots provided a visual means of comparing the distributions of counts between samples, and
shown lower, median and upper quantiles and counts for outlying features. (C) MvA plot shows the
log2fold changes of OAT-H vs. WAT attributable to a given variable of the mean of normalized counts
for all samples. Red points indicate a variable with an FDR-p-value < 0.1, and points falling outside
of the plotting area are depicted as open triangles pointing either up or down. (D) A PCA plot was
summarized at the sample-level following the exclusion of non-informative features (total counts across
all samples < 1) for the top 500 genes in terms of highest variance (Table S1B).
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In DGE analysis comparing OAT-H vs. WAT, we obtained 3790 genes with FDR-p significant
(<0.05), which has 1746 genes (7.35%) up-regulated and 2044 genes (8.6%) down-regulated. A
summarized log2fold change of genes over the mean of normalized counts is shown in the MvA
plot (Figure 4C). A PCA-plot at sample-level (Figure 4D) showed a clear separation of samples
from OAT-H or WAT that used the top 500 genes (FDR < 0.05) with highest variance (DGE data in
Table S1B).
2. DGE analysis comparing OAT-H with WAT confirmed substantially lower expression levels of
MFN2 and LEP, as well as a significantly increased expression of LEP receptor (LEPR) (Table S1A).
Lower expression level of ADIPOQ (adiponectin) was seen in OAT-H compared with WAT with
no difference in ADIPOQ receptors (Table S1A). In further analysis, we used a setting of log2fold
> 0.5 or <−0.5; FDR-p < 0.05, and obtained 3277 genes (1495 up and 1782 down-regulated) for
IPA® analysis. The up- or down-regulated gene set of OAT-H versus WAT was also subject
to IPA® analysis. Pathway analysis suggested substantially reduced lipid metabolic activity
(overlap-p < 0.01; z-score < −2) including FA metabolism, lipid uptake, uFAs conversion, lipolysis,
lipid synthesis, and oxidation of lipid (e.g., ACADM, ECHS1) compared with WAT (Table S2).
This evidence for reduced lipid metabolic activity was further supported by IPA® analysis of
down-regulated genes. Furthermore, we identified significantly increased expression of the FA
transporter, SLC27A6, in OAT-H compared with WAT.
3. Targeted QPCR analysis of genes highlighted in the whole transcriptome analysis confirmed
substantially lower levels of elements of lipid metabolism including lipid uptake (LPL), lipolysis
(LIPE) and uFAs conversion (SCD), and substantially up-regulated SLC27A6 (FA transporter) in
OAT-H, when compared with WAT (Figure 5A–D). SLC27A6 has been reported as a transporter
for long chain FAs uptake (>14 carbons) [27,28].
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Figure 5. QPCR analysis of lipid metabolisms of OAT compared with WAT. Total RNA was isolated
from OAT-H (n = 4), OAT-GO (n = 9) and WAT (n = 6) ex vivo fat tissues. LPL (A), LIPE (B), SCD (C)
and SLC27A6 (D) were analyzed using relative ratio of gene expression by QPCR, and housekeeper
gene APRT served as the reference gene. Histograms = mean ± SEM of all samples studied. * p < 0.05;
** p ≤ 0.02; *** p ≤ 0.005.
In OAT-GO samples, LIPE transcripts (lipolysis) remained low, while variable LPL (lipid uptake)
and SCD (uFAs conversion) expression levels were detected, not significantly different compared
to WAT by QPCR analysis (Figure 5A–C). The lack of significant difference of FASN (fatty acid
synthase) mRNA transcripts between OAT-H, OAT-GO and WAT was confirmed in QPCR analysis
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(Figure S1), as well as the further increase in SLC27A6 expression in OAT-GO compared to OAT
(Figure 5D).
2.5. Signatures of Biological and Signaling Pathways in OAT by IPA® Analysis
1. Substantially lower expression of the Homeobox (HOX) families (A, B, C, D) were observed in
OAT-H compared with WAT (sub-grouped in Table S1A). HOXA5, HOXA6, HOXC8 and T-box
transcription factor 5 (TBX5) were among the top most lowly expressed genes in OAT-H and
relate to embryonic development of WAT/BAT (highlighted in Table S1B) [9,10]. Upregulation in
the Iroquois homeobox gene family (IRX3 and IRX5), which play a role in an early step of neural
and adipose tissue development, was observed in OAT-H [29,30]. The top ten up-regulated genes
in OAT-H are shown in Table S1B.
2. In IPA®, in addition to the changes in lipid metabolisms detailed above, substantially lower
activity (overlap-p < 0.01; z-score < −2) was seen in pathways of cell movement and molecule
transport in OAT-H compared with WAT (Table S2). In agreement with this, signaling pathways
showed substantially lower activity in OAT-H of oxidative phosphorylation (OXPHOS), glycolysis,
gluconeogenesis, glycogen degradation and cAMP-mediated signaling (Table S3). Furthermore,
IPA® of down-regulated genes further supported the observed lower metabolic activity and
signaling pathways of OAT-H compared with WAT (Supplementary Materials Tables S2 and S3).
3. Certain signaling pathways were substantially activated (overlap-p < 0.01; z-score > 2, IPA®
analysis) in OAT-H compared with WAT. (A) Activation of Wnt/Ca+ signaling pathway [31]
was observed, as indicated by 11 up-regulated genes including Wnt family members (Wnt5A
and Wnt5B) (Table S3). (B) Components of fibroblast growth factor (FGF) signaling [32] were
significantly increased in OAT-H compared to WAT including FGF family and FGF-receptor
2 (FGFR2) (Table S3). Furthermore, we observed significantly increased expression of IGF2,
IGF1R, IGF-binding proteins (IGFBP4&6, IGF2BP2) but down-regulated IGF1, IGFBP3 and Akt1
expression [33] (Table S1A). (C) Activation of Sirtuin signaling pathway [34] was observed as
indicated by 11 up- and 64 down-regulated genes in IPA® analysis (Table S3).
4. Additional up-regulated genes in OAT-H compared to WAT included expression of molecules
(e.g., neuronal biomarkers, NRGN [35] and SNAP25 [36]) associated with neurogenesis (see Table
S2) including development of neurons, proliferation of neuronal cells, differentiation of neurons,
outgrowth of neuritis, neurotransmission and neuritogenesis.
5. Up- and down-regulated expression of growth factors of interest in OAT-H compared with WAT
are summarized in Table 1. The up-regulated (range of ~2 to 45-fold, Table S4) growth factors
interfere with signaling pathways including TGFβ/Wnt/Ca+/FGF/Notch/MAPK/PI3K, potentially
relevant to a wide range of biological processes of OAT [31,37,38].
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Table 1. Up- and down-regulated growth factors in OAT-H compared to WAT.
Up-Regulated Growth Factor
(Multi-Function 1) Known Function/Pathway
Angiopoietin (ANGPT4) [39] angiogenesis
Osteoglycin (OGN) [40] bone formation
Neural EGF-like protein (NELL1) [41] bone formation
TGFβ family 1 [42]
(TGFB2, BMP3, GDF-6,7,11)
and Latent TGFβ binding protein 1 (LTBP4)
TGFβ signaling pathway
Jagged 1 protein (JAG1) 1 [43] Notch signaling pathway
Midkine (MDK) 1, Pleiotrophin (PTN) 1 [44] multi-signaling pathway
Norrin cystine knot growth factor (NDP) 1 [45] Wnt-signaling pathway
Hepatocyte growth factor (HGF) 1 [46] HGF/Met signaling pathway
FGF-(7,9,10,17&18) 1 via FGFR [32] multi-signaling pathway
IGF2 1 via IGF1R/IGF2R [33] multi-signaling pathway
Down-regulated growth factors as below
TGFA, BMP6, GDF10, IGF1, FGF-2,8&13, VEGF-B&D, GMFG, JAG2, LEFTY2, LEP and PDGF-B&C
1 Indicated in the table as functioning in multi-cellular processes, e.g., mesenchymal stem cell (MSC) proliferation
and differentiation.
3. Discussion
3.1. OAT Is Distinct from WAT and BAT/BRITE
Our study has highlighted several differences in OAT, which distinguish it from WAT and
BAT/BRITE. These are summarized in Table 2. Unlike WAT, OAT has low level LEP expression
and no hypertrophy but displays the hyperplasia characteristics of BAT/BRITE as evidenced by
smaller adipocyte in OAT-H and OAT-GO compared to WAT. However, in contrast to BAT/BRITE,
OAT and WAT have a single lipid vacuole, low levels of UCP1 and MFN2 expression and similar
mitochondria number per adipocyte. Furthermore, OAT is of neural crest origin consistent with this
study, identifying substantially lower expression of HOX-gene families and TBX5, which play an
essential role in WAT/BAT development from mesoderm origin [9,10].
Table 2. Summary of key features of WAT and BAT/BRITE in OAT from this study.
OAT-H OAT-GO WAT BAT/BRITE [17,20]
Hypertrophy (Figure 1) - - +++ -
LEP (WAT marker) (Figure 2) — — +++ —
Hyperplasia (Figure 1) +++ +++ - +++
Lipid vacuole (Figure 1) - - - +++
Mt number/adipocyte (Figure 1) - — - +++
UCP1 (BAT marker) (Figure 2) — - - +++
MFN2 (Mt marker) (Figure 2) — - - +++
LIPE (Lipolysis, Figure 5) - - +++
LPL (FA uptake, Figure 5) - +++ +++
SCD (uFAs conversion, Figure 5) — - -
FASN (FA synthesis, Figure S1) - - -
Linoleic acid (essential FA, Figure 3) +++ +++ +++
de novo lipogenesis (SCD, Linoleic
acid and FASN) - - -
Stearic acid (Figure 3) +++ +++ -
SLC27A6 (transporter) (Figure 5) +++ +++ -
Key findings of molecular, lipid profile and function differences in OAT have been shown in Table 2, Mt, mitochondria;
‘-’ low level (or single vacuole), ‘—’ lower level, ‘+++’ high level (or multi vacuole)).
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The difference between OAT-H and OAT-GO has also been summarized in Table 2, which will be
discussed in the following Sections 3.2 and 3.5.
3.2. Expression of a Distinct FA Transporter in OAT
Our data suggest that there are important differences in the mechanism of adipogenesis in OAT as
compared to WAT. Our finding of similar levels of essential linoleic acid and low FA synthesis (de
novo lipogenesis) in OAT-H/OAT-GO as in WAT (Table 2) suggest that the depot specific hyperplastic
expansion of OAT is FA-uptake driven [22]. This pathologically enhanced FA-uptake in OAT in GO,
evidenced by limited lipolysis (LIPE) and inducible FA-uptake (LPL), may occur via a depot specific
FA transport system, for example, SLC27A6. SLC27A6 belongs to the FAs transporter family to uptake
long-chain FAs functioning in heart or non-tumorigenic breast cells and is absent or only expressed at
low levels in WAT [27,28].
3.3. OAT Is not Implicated in Maintenance of Energy Balance
Albeit OAT appears to have its stored triglyceride originating externally, it does not store additional
triglyceride under conditions of caloric excess in obesity [11]. The low expression levels of leptin
and adiponectin, substantially increased leptin receptor and unaltered adiponectin receptor that we
observed in the current study indicate that OAT has a role other than maintaining energy balance
as do WAT/BAT [17]. In addition to the well-known negative feedback feeding mechanism, leptin
via its receptor has direct negative impact on lipid metabolism and is also involved in later neural
development, for example, neurogenesis [47,48].
3.4. RNAseq Data Provide Additional Insight into Role of IGF-1 Signaling in GO
Previous studies have demonstrated that pathological activation and cross-talk of TSHR
and IGF1R play essential roles in OAT expansion in GO via a depot specific signaling pathway,
IGF1R/PI3K/FOXOs [1,2]. This has been emphasized by a recent clinical trial, in which anti-IGF1R
therapy (teprotumumab), dramatically reduced proptosis in GO patients [5,7]. The FGF signaling
pathway has also been shown to be important in OAT expansion in GO [32]. The activation of
FGF/FGFR increases the expression of IGF2, which together play important regulatary roles in MSC
via IGF2/IGF1R axis [33]. Our current study has demonstrated that FGFs, FGFR2, IGF2 and IGF1R
were highly expressed in OAT-H compared with WAT, consistent with the clinical benefits of IGF1R
inhibition in GO.
3.5. Hypothesis of Dysfunction of Mitochondria in OAT Expansion in GO
TSHR activation significantly increases UCP1 expression in OAT, and expansion of OAT and BAT
has been reported following overexpression of adiponectin [23–25]. Both adiponectin and UCP1 play
important roles in mitochondrial function [49,50]. Our current study showed an activated Sirtuin
signaling pathway in OAT-H indicating a potential involvement of mitochondria in OAT metabolism
also [34]. Furthermore, we observed pathologically increased expression levels of UCP1/MFN2
in OAT-GO compared to OAT-H. Taken together these data suggest a role for mitochondria in
the hyperplasia/adipogenesis of OAT expansion in GO. This hypothesis echoes a recent report of
uncontrolled hyperplasia/adipogenesis of BAT expansion linked with dysfunction of mitochondria [51].
3.6. Weaknesses and Strengths
The weakness of our study is that many of our results rely on gene transcriptional expression.
We performed protein analysis of UCP1 and mitochondrial markers using immunofluorescence and
confocal microscopy; however, low levels of mitochondrial number per adipocyte and expression of
relevant markers in WAT/OAT-H/OAT-GO prevented us from obtaining meaningful results.
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The strength of our study is the use of human ex vivo adipose tissues, including paired samples of
OAT-H and WAT from people free of GO and Graves’ disease, which eliminated individual variation
in lipidomic analysis. The main observations from this study have been replicated in more than one
independent technique.
3.7. Speculations from Current Study
Our study demonstrates a unique adipose tissue with depot specific gene expression of IRX3 and
IRX5, which is implicated in the early development of adipose and neural tissue in OAT [29,30]. Apart
from maintaining basic lipid metabolism in OAT, transcript profiles were consistent with the potential
for neurogenesis, including neuronal biomarkers, for example, high expression of NRGN [35] and
SNAP25 [36], TGFβ family [42], JAG1 [43], MDK & PTN [44], and activation of the Wnt/Ca+ signaling
pathway [31]. The innervation of peripheral nerves in WAT/BAT has been established and plays an
important role in lipid metabolism and regulation of energy balance [52,53]. Future work to explore
further OAT specific neurogenesis and lipid metabolisms would be of great interest.
Studies have shown the multi-differentiation potentials of OAT-PFs as MSC [54]. Our
work suggests that OAT-produced growth factors interacting with multiple signaling pathways
(TGFβ/Wnt/Ca+/FGF/Notch/MAPK/PI3K) that support repair mechanisms such as adipogenesis,
osteogenesis, myogenesis, chondrogenesis, neurogenesis and angiogenesis [31–33,37–46]. Furthermore,
we have demonstrated a depot specific triglyceride composition of OAT, for example, stearic acid (18:0
FA), a stable waxy solid fat. This specific triglyceride composition may facilitate its role in supporting
constant eye movement [3,55].
The smaller adipocytes, FA-uptake driven adipogenesis of PFs and hyperplastic adipocyte
expansion in GO from the current study revealed a key role of the pathological enhanced proliferation
of MSC and PFs in OAT in GO. We have previously reported increased proliferation of PFs from OAT-GO
compared with OAT-H [56], using the same in vitro models as in this study, our findings agree with that
of others [54,57]. Furthermore, our work emphasizes the importance of anti-proliferation therapies, for
example, prostaglandin F2α, by targeting MSC/PFs in OAT in GO reviewed in [2]. Future investigation
is needed to explore the mechanism triggering MSC/PF proliferation in the autoimmune/inflammatory
environment in GO [2] and its possible link with mitochondrial dysfunction [51].
3.8. Clinical Impact from Current Study
Our study has demonstrated a depot-specific FA-uptake driven OAT expansion with limited
lipolysis in GO. Lipolysis of WAT leads to elevated plasma free FA in Graves’ disease as a consequence of
TSHR activation and hyperthyroidism [58–62], which are also major contributors for GO development [1,
2]. It is possible that the free FAs from lipolysis of WAT provide resources for the FA-uptake driven
adipogenesis of OAT in GO. Interestingly, a 40% decreased GO risk in Graves’ disease was observed
with statin therapy but not non-statin cholesterol-lowering medications [63]. Studies have reported
that statin lowers plasma cholesterol and also free FAs [64]. Furthermore, up to 3-fold elevated
free FAs were observed from smoking individuals [65], and smoking is also a known risk factor of
GO [66]. Together with our current study, these data suggest that excessive FAs may contribute to OAT
expansion in GO in addition to immune/inflammatory mechanisms [2].
Current therapy for moderate to severe GO comprises high dose intravenous steroids, with
some evidence for benefit with immunosuppressive agents and anti- IGF1R therapy [2]. However,
for a majority of patients, significant disfigurement persists with a major impact on quality of life
and the need for extensive orbital rehabilitative surgery [67]. Our current study suggests that better
control of free FAs available for OAT expansion might be beneficial for GO patients in prevention and
post-clinical management.
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3.9. Conclusions
OAT appears to have many features that are different from WAT or BAT/BRITE. We have observed
a quiescent fat depot of OAT. When hyperplasia/adipogenesis is triggered as in GO, FA synthesis
(de novo lipogenesis) and lipolysis remains low, suggesting there has been abundant uptake of
exogenous FAs [1,2]. The observation of high expression of a specific FA transporter, SLC27A6,
suggests that the process may be triggered by facilitated FA uptake. Our work has also raised the
possibility of mitochondrial dysfunction playing a part in the hyperplastic expansion of OAT in GO
as occurs in BAT [51]. Furthermore, we illustrated a unique gene signature of OAT with activated
signaling pathways and potential production of necessary growth factors to support depot specific
OAT metabolism in its role supporting tissues embedded behind the eye. Further targeted experiments
are required to confirm and extend these findings.
4. Materials and Methods
All reagents were obtained from Sigma-Aldrich (Dorset, UK) and tissue culture components from
Cambrex (Thermo Fisher Scientific, Waltham, MA, USA) unless otherwise stated.
4.1. Adipose Tissue Collection and Preparation
Human Adipose Tissue was collected with informed written consent and approved by the
South East Wales Research Ethics Committee (30 May 2006) with registry number (06/WSE03/37).
WAT (subcutaneous) was from 10 patients undergoing elective open abdominal or breast surgery for
non-metabolic conditions. OAT from GO patients (OAT-GO) (n = 10) were from 7 inactive GO patients
with a CAS (clinical activity score) < 2, 3 active GO with CAS ≥ 3 undergoing decompression surgery.
Healthy OAT (OAT-H) from nonGO patients (n = 6) were free of thyroid or other inflammatory eye
disease who underwent augmented blepharoplasty. Adipose tissues were snap-frozen, kept in liquid
nitrogen for later ex vivo analysis (all samples summarized in Table 3).
Table 3. Ex vivo samples from WAT, OAT-H and OAT-GO used for this study.
ID Sex Age GO Status Analysis
OAT-H1 F 51 no RNAseq(1.06)
OAT-H2 F 64 no RNAseq(0.97)
OAT-H3 F 64 no RNAseq(0.87)/Lipidomic/adipocyte
OAT-H4 F 76 no RNAseq(1.09)/adipocyte
OAT-H5 F 37 no Lipidomic
OAT-H6 F 46 no Lipidomic
OAT-GO1 F 47 active Lipidomic/QPCR/adipocyte
OAT-GO2 M 49 active QPCR/adipocyte
OAT-GO3 M 78 active QPCR
OAT-GO4 F 16 inactive Lipidomic/QPCR
OAT-GO5 F 56 inactive Lipidomic/QPCR
OAT-GO6 M 45 inactive QPCR
OAT-GO7 M 60 inactive adipocyte
OAT-GO8 F 55 inactive adipocyte
OAT-GO9 M 29 inactive adipocyte/PCR
OAT-GO10 F 47 inactive QPCR
WAT1 F 72 no RNAseq(1.02)/QPCR
WAT2 F 72 no RNAseq(0.97)/QPCR
WAT3 F 44 no RNAseq(1.00)/QPCR
WAT4 F 62 no RNAseq(1.22)/QPCR
WAT5 F 50 no RNAseq(0.95)/QPCR
WAT6 F 37 no Lipidomic/QPCR/adipocyte
WAT7 F 64 no Lipidomic/QPCR/adipocyte
WAT8 F 46 no Lipidomic
WAT9 M 49 no QPCR
WAT10 M 54 no QPCR
Patients age, sex and GO status are shown in the table. The types of analysis have been shown for each sample as
adipocyte, QPCR, lipidomic, and RNAseq analysis is followed by DESeq2 size factor in brackets.
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4.2. Adipocytes Analysis in Ex Vivo Adipose Tissues by Light Microscopy
Adipocytes were analyzed from WAT (n = 2, total 254 cells), OAT-H (n = 2, total 651 cells) and
OAT-GO (n = 5, 2 active GO (total 591 cells) and 3 inactive GO (total 1480 cells)) (Table 3), adapted
from the previously described method [68]. In brief, adipose tissues were thawed in 4% formaldehyde
+ 0.2% glutaraldehyde in 300mM phosphate buffer (pH 7.4), cut into 1mm thick slices and fixed for 24h.
Samples were then post-fixed for 2h in 2% aqueous uranyl acetate followed by full dehydration in
isopropanol (50%, 70%, 90% 10 min each, 100% 2 × 15 min) and infiltration with LR White acrylic resin
(London Resin Company, Reading, U.K.) (50% in isopropanol 30 min, neat resin 4 × 20 min). Samples
placed in resin-filled size 0 gelatine capsules and polymerized overnight at 50 ◦C. Sections (0.35µm)
were cut on an Ultracut E ultramicrotome and stained with 1% toluidine blue. Sections were examined
with an Olympus BX51 research light microscope (Olympus Optical Co. Ltd., London, UK) and digital
photomicrographs captured with a Zeiss Axiocam and Axiovision software (Carl Zeiss Vision GmbH,
Hallbergmoos, Germany). Adipocytes were segmented manually, by drawing around the outer edge
of the fat reservoir, and areas calculated using Image J software (v1.51w).
4.3. Electronic Microscopy Analysis of Adipocytes and Mitochondria in Ex Vivo Tissues
Thin (100nm) sections of WAT (n = 2), OAT-H (n = 2) and OAT-GO (n = 1, active GO1) (Table 3)
were cut on an Ultracut E ultramicrotome onto 200 mesh formvar/carbon-coated grids, stained with lead
citrate, and examined with an Hitachi HT7800 TEM at 80kV (Hitachi High Technologies Corporation,
Tokyo, Japan) and digital images acquired with a Megaview G3 camera and Radius software (EMSIS
GmbH, Muenster, Germany). Mitochondria in each adipocyte were counted and measured (length
and width) from WAT (37 adipocytes), OAT-H (39 adipocytes) and OAT-GO (33 adipocytes) using
Image J software (v1.51w).
4.4. QPCR for Markers of Adipose Tissues of WAT, BAT/BRITE and OAT
The ex vivo tissues have been analyzed using the primers listed in Table S5. Total RNA was
extracted and cDNA were synthesized using standard protocols for QPCR analysis of mRNA expression
as described before [69]. QPCR was conducted using Invitrogen® SYBR® Green QPCR SuperMix-UDG
on a Stratagene MX 3000 with 50 ◦C 2 min; 95 ◦C 2 min; 40 cycles of 15 s 95 ◦C and 30 s 60 ◦C. The
relative expression ratio of the targeted gene was calculated using the detected Ct value in comparison
to a reference gene (housekeeping gene APRT (adenosine phosphoribosyl transferase)) by the standard
method [70].
4.5. RNA-Seq Sample Preparation and Sequencing
Total RNA was isolated OAT-H (nonGO female individuals, n = 4, age 63.8 ± 5.1) and WAT
(nonGO female patients, n = 5, age 60 ± 5.7) as shown in Table 3, the quality and quantity was assessed
using Agilent 2100 Bioanalyzer and a RNA Nano 6000 kit (Agilent Technologies, Santa Clara, CA,
USA). A total of 900ng of Total RNA with a RIN value >8 was depleted of ribosomal RNA and the
sequencing libraries were prepared using the Illumina® TruSeq® Stranded Total RNA with Ribo-Zero
Gold™ kit (Illumina Inc., San Diego, CA, USA). The steps included rRNA depletion and cleanup, RNA
fragmentation, 1st strand cDNA synthesis, 2nd strand cDNA synthesis, adenylation of 3′ ends, adapter
ligation, PCR amplification (12-cycles) and validation. The manufacturer’s instructions were followed
except for the cleanup after the ribozero depletion step where Ampure®XP beads (Beckman Coulter,
High Wycombe, UK) and 80% Ethanol were used. The libraries were validated using the Agilent
2100 Bioanalyzer and a high-sensitivity kit (Agilent Technologies, Santa Clara, CA, USA) to ascertain
the insert size, and the Qubit® (Thermo Fisher Scientific, Waltham, MA, USA) was used to perform
the fluorometric quantitation. Following validation, the libraries were normalized to 4nM, pooled
together and clustered on the cBot™2 following the manufacturer’s recommendations. The pool was
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then sequenced using a 75-base paired-end (2 × 75 bp PE) dual index read format on the Illumina®
HiSeq2500 in high-output mode according to the manufacturer’s instructions.
4.6. RNA-seq Read Alignment and Differential Expression Analysis
Preprocessed RNA-Seq reads were quality checked (QC) using FastQC v0.11.8 (Babraham Institute),
then trimmed of the adapter and low quality read ends using Trim Galore! v0.6.0 (Babraham Institute).
Trimmed reads were mapped to Gencode GRCh38 release 32 primary assembly [71] using the STAR
v2.5.1b 2-pass method [72]. RSeQC (v3.0.1) infer_experiment.py was used to infer library strand
specificity from sequence alignment files (.bam). Then read counts were summarized at exon level
and aggregated gene level, specifying strandedness, using Subread FeatureCounts (version 2.0.0) [73],
where features were defined by the GRCh38 v32 comprehensive primary assembly gene annotation
superset. Normalized counts of genes were generated from raw counts by division of the DESeq2
size factor (Table 3) of each sample (DESeq2 v1.24.0) in differential gene expression (DGE) analysis
(R/Bioconductor DESeq2 package) [26]. Log2-fold changes of OAT-H compared to WAT were obtained,
and the resultant p-values were corrected for multiple testing and false discovery using the FDR method
of Benjamini–Hochberg. A FDR-corrected p-value (FDR-p) threshold of less than 0.05 was used as the
criteria for the identification of significantly differentially expressed transcripts. Variance stabilizing
transformation counts of genes were generated to present a constant variance for visualization analysis
of boxplots and PCA plot at sample level using R/Bioconductor DESeq2 package.
4.7. Ingenuity® Pathway Analysis (IPA®, Qiagen)
DGE data set of OAT-H versus WAT was used for IPA® (version 01-07) with a setting of log2-fold >
0.5 or <−0.5; FDR-p-value < 0.05 (Supplementary Materials Table S1). The down- or up-regulated gene
set was also analyzed separately. IPA Core Analysis was used to investigate the molecule connectivity
(networks), biology functions, and involvement in signaling pathways of OAT-H compared to WAT.
The biological activities of OAT genes were analyzed by Fisher’s Exact Test, in which an overlap
p-value (overlap-p) < 0.01 is considered as a significant overlap between our data and the known gene
functions stored in Ingenuity® Knowledge Base. Z-score was calculated by IPA® reflecting the overall
predicted activation state of OAT biological activities (<−2: inhibited, >2: activated). Ratio shows the
mapping number of genes from the current study divided by the total number of genes from the same
pathway by Ingenuity® Knowledge Base.
4.8. Gas Chromatography (GC) Analysis of Triglyceride FAs
Total lipids were extracted from paired OAT-H and WAT from 3 healthy female individuals (age
49 ± 13.7) (Table 3), and also from 3 unpaired OAT from GO female patients (age, 57.3 ± 18), triglyceride
separated and analyzed by GC, as previously described [74]. FA concentrations were calculated relative
to the internal standard and results were expressed as a mole percentage of triglyceride.
4.9. Statistical and Bioinformatics Analysis
Results were analyzed and a t-test (normally distributed data) or nonparametric test was used
in this study. Differences between groups were analyzed using ANOVA. In all cases p < 0.05 was
considered significant. Data are presented as mean ± SEM in this study. Specified FDR-p-value for
RNAseq data analysis and overlap-p-value and z score for IPA® analysis have been described above in
their sections.
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LIPE hormone-sensitive lipase
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